Liquidity & Technicals

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Portfolio Implementation Verdict

ADANIENT trades $3.8M per day on a 20-day average — thin relative to its $35B market cap, constrained by a 74.67% promoter lock-up that leaves under 25% effective free float. The technical stance is neutral: price just reclaimed the 200-day SMA on a sharp +32.5% one-month rally, but the death cross (50d under 200d) remains active and RSI is overbought at 76.

5-Day Capacity 20% ADV ($M)

4.3

Max Position (% MCap, 5d)

0.012%

Fund AUM for 5% Pos ($M)

86

ADV 20d (% MCap)

0.011%

Technical Score (+3 to -3)

1

Price Snapshot

Current Price ($)

26.83

YTD Return

6.8%

1Y Return

-0.3%

52-Week Position (%)

69.8

Beta

-

Full-History Price with 50/200 SMA

Loading...

Price is above the 200-day SMA ($26.83 vs $25.53). The current regime is a sharp recovery rally within a broader downtrend — price traded below the 200d from November 2024 through late April 2026, and has only just reclaimed it. The 50d SMA ($23.17) remains well below the 200d, meaning the December 2025 death cross is still structurally active.


Relative Strength vs Benchmark

Loading...

Benchmark data (INDA) was not available in the staging files. The chart shows ADANIENT's absolute performance rebased to 100 from March 2023. Over this 3-year window, the stock is up ~40% from its post-Hindenburg recovery base but remains 42% below its January 2023 all-time high of $46.63.


Momentum — RSI and MACD

Loading...
Loading...

RSI has surged from 32 (late March, near oversold) to 76 (current, overbought) in under a month — the sharpest momentum swing in 18 months. MACD histogram has flipped decisively positive with the largest bullish bars since the September 2025 rally. Near-term momentum is strongly bullish but the overbought RSI reading means pullbacks are probable within 1-3 weeks.


Volume, Volatility, and Sponsorship

Loading...
No Results

The two largest volume spikes in the dataset are associated with sharp sell-offs (Jun 2024: -19.4%, Nov 2024: -22.6%), consistent with forced selling or institutional exit events. The March 2025 spike (+4.6%, 33.5x average) was a reversal/recovery day. Volume has surged in March-April 2026 as the current rally drew participation.

Loading...

Current 30-day realized volatility is 42.8%, sitting between the 50th percentile (39.7%) and 80th percentile (55.0%) of its 10-year history — elevated but within the normal regime. The Hindenburg episode of early 2023 produced a record spike to 185%, dwarfing all other readings. The November 2024 sell-off generated an 80% vol reading. This stock has tail-risk episodes that push volatility to extremes. The market is demanding a wider risk premium but has not entered a stressed regime.


Institutional Liquidity

A. ADV and Turnover

ADV 20d (Shares)

160,872

ADV 20d ($M)

3.8

ADV 60d (Shares)

231,180

ADV 20d (% MCap)

0.011%

Annual Turnover (%)

2.7

B. Fund-Capacity Table

No Results

C. Liquidation Runway

No Results

D. Execution Friction

Median daily range over 60 days: 2.86% — above the 2% threshold, indicating elevated impact cost for block-level orders. Combined with the thin ADV, this means any meaningful institutional position will move the stock.

At 20% ADV participation, the largest position that clears in five trading days is approximately $4.3M (0.012% of market cap). At the more conservative 10% participation rate, that falls to $2.2M. These are small numbers for a company with a $35B total market cap — the tight promoter lock-up is the root cause. A fund with under $86M AUM could take a 5% position over five days at 20% ADV; larger funds would need to build slowly over multiple weeks or accept significant market impact.


Technical Scorecard and Stance

No Results

Total: +1 (Neutral)

Stance: Neutral on the 3-to-6 month horizon. The +32.5% one-month rally is the strongest short-term move since September 2025 and has pushed price back above the 200-day SMA — a necessary but not sufficient condition for a trend reversal. The death cross remains structurally active with SMA50 at $23.17, still 9% below SMA200 at $25.53. RSI is overbought at 76, making a near-term pullback probable. The stock is 42% below its all-time high and the one-year return is flat, so while the tape is improving it has not confirmed a new uptrend. A sustained break above $30.00 (52-week high) would confirm bullish reversal and shift the view to bullish. A failure to hold $23.15 (50-day SMA / March support) would confirm the downtrend and shift the view to bearish. Liquidity is the constraint — a fund targeting more than a 5% position would need to build over multiple weeks at 20% ADV, and even small institutional positions (0.5% of market cap) take over 200 days to exit. The correct posture for size-constrained funds is watchlist with patient accumulation on pullbacks toward the 50-day SMA.